Trial Profile
Dbl-Blind, Rand Phase 1/2a Human Challenge Study, to Eval Safety, Reactognty, Immunognty and Preliminary Efficacy After Sporozoite Challenge/Rechallenge of Vaccines Containing RTS,S.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs GSK 257049 (Primary)
- Indications Falciparum malaria; Malaria
- Focus Adverse reactions; Pharmacodynamics
- 31 Mar 2020 Results (n=45) assessing functional antibodies and protection against controlled human malaria infection challenge were published in the Journal of Infectious Diseases
- 10 Feb 2018 Results of pooled analysis of this and other five phase II studies assessing relationship between HLA allele groups and RTS,S-mediated protection in controlled human malaria infections, published in the Vaccine.
- 12 Jan 2010 Actual end date (Jan 2006) added as reported by ClinicalTrials.gov.